Recent News

• 03.06.2026 - Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
• 02.25.2026 - Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
• 02.24.2026 - Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
• 02.11.2026 - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
• 01.08.2026 - Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
• 01.05.2026 - The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)

Recent Filings

• 02.25.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2026 - 8-K Current report
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.30.2025 - 4 Statement of changes in beneficial ownership of securities